2024-516197-30-00RecruitingPhase 1
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability after multiple-dose administration of three different doses of naronapride in patients with moderate idiopathic or diabetic gastroparesis compared to healthy subjects
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Enrollment
- 24
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CTIS – Scientific Request
Scientific
Dr. Falk Pharma GmbH
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
Comparison of systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept in patients with visual impairment due to diabetic macular edemaVisual impairment due to diabetic macula edemaMedDRA version: 17.0Level: PTClassification code 10012689Term: Diabetic retinopathySystem Organ Class: 10015919 - Eye disordersEUCTR2014-001639-35-DEovartis Pharma GmbH40
Active, not recruiting
Phase 1
Comparison of systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept in patients with neovascular (wet) age-related macular degeneratioVisual impairment due to neovascular AMDMedDRA version: 19.0Level: LLTClassification code 10060837Term: Choroidal neovascularizationSystem Organ Class: 100000004853EUCTR2014-001182-27-DEovartis Pharma GmbH40
Recruiting
Phase 2
A multi-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin α10β1-selected mesenchymal stem cells (XSTEM-VLU) in patients with difficult-to-heal venous leg ulcers2024-518757-42-00Xintela AB6
Completed
Not Applicable
A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers.NL-OMON35929Ablynx NV76
Completed
Phase 1
A study to investigate the safety, tolerability and activity of multiple ascending doses of DNDI-0690 in healthy volunteers including assessment of heart and kidney functioThe safety, tolerability and fluid exposure of a drug aimed to treat visceral and cutaneous leishmaniasis in healthy volunteersISRCTN30122193Drugs for Neglected Diseases Initiative45